The Norwegian Immunotherapy in Multiple Myeloma Study - A Population-based Longitudinal Observational Multicenter Study on Effectiveness and Complications of Immunotherapy in Multiple Myeloma in the Norwegian Myeloma Cohort
The goal of this observational study is to study the effectiveness and complications of novel immunotherapies used in the treatment of multiple myeloma in routine care in Norway. The aim is to close knowledge gaps, generate evidence for future clinical trials and contribute to future consensus on how to monitor for adverse events, and what mitigation strategies should be implemented, so that we can increase patient survival and quality-of-life.
• Participants age ≥ 18 years
• Prior diagnosis of one of the following
‣ Multiple myeloma as defined according to IMWG criteria
⁃ Primary plasma cell leukemia as defined according to IMWG consensus definition
⁃ AL-amyloidosis as defined according to IMWG criteria
• Planned treatment with one of the following outside clinical trials (list to be amended based on approvals within the EU):
‣ Teclistamab (Tecvayli)
⁃ Elranatamab (Elrexfio)
⁃ Talquetamab (Talvey)
⁃ Idecabtagene vicleucel (ide-cel/Abecma)
⁃ Ciltacabtagene autoleucel (cilta-cel/Carvykti)